nach oben

EJNMMI Research

Erschienen in:

Open Access 01.12.2017 | Original research

Test-retest reproducibility of [¹¹C]-l-deprenyl-D₂ binding to MAO-B in the human brain

verfasst von: Ryosuke Arakawa, Per Stenkrona, Akihiro Takano, Sangram Nag, Rafael S. Maior, Christer Halldin

Erschienen in: EJNMMI Research | Ausgabe 1/2017

Abstract

Background

[¹¹C]-l-deprenyl-D₂ is a positron emission tomography (PET) radioligand for measurement of the monoamine oxidase B (MAO-B) activity in vivo brain. The estimation of the test-retest reproducibility is important for accurate interpretation of PET studies.

Results

We performed two [¹¹C]-l-deprenyl-D₂ scans for six healthy subjects and evaluated the test-retest variability of this radioligand. MAO-B binding was quantified by two tissue compartment model (2TCM) with three rate constants (K ₁, k ₂, k ₃) using metabolite-corrected plasma radioactivity. The λk ₃ defined as (K ₁/k ₂) × k ₃ was also calculated. The correlation between MAO-B binding and age, and the effect of partial volume effect correction (PVEc) for the reproducibility were also estimated. %difference of k ₃ was 2.6% (medial frontal cortex) to 10.3% (hippocampus), and that of λk ₃ was 5.0% (thalamus) to 9.2% (cerebellum). Mean %difference of all regions were 5.3 and 7.0% in k ₃ and λk ₃, respectively. All regions showed below 10% variabilities except the hippocampus in k ₃ (10.3%). Intraclass correlation coefficient (ICC) of k ₃ was 0.78 (hippocampus) to 0.98 (medial frontal cortex), and that of λk ₃ was 0.78 (hippocampus) to 0.95 (thalamus). Mean ICC were 0.94 and 0.89 in k ₃ and λk ₃, respectively. The highest positive correlation with age was observed in the hippocampus, as r = 0.75 in k ₃ and 0.76 in λk ₃. After PVEc, mean %difference were 5.6 and 7.2% in k ₃ and λk ₃, respectively. Mean ICC were 0.92 and 0.90 for k ₃ and λk ₃, respectively. These values were almost the same as those before PVEc.

Conclusions

The present results indicate that k ₃ and λk ₃ of [¹¹C]-l-deprenyl-D₂ are reliable parameters for test-retest reproducibility with healthy subjects both before and after PVEc. The studies with patients of larger sample size are required for further clinical applications.

2TCM

Two tissue compartment model

AAL

Anatomical Automatic Labeling

Alzheimer’s disease

ALS

Amyotrophic lateral sclerosis

CSF

Cerebrospinal fluid

FWHM

Full width at half maximum

Grey matter

HRRT

High resolution research tomograph

ICC

Intraclass correlation coefficient

MAO

Monoamine oxidase

MRI

Magnetic resonance image

MSBS

Mean square of between subject

MSWS

Mean square of within subject

PET

Positron emission tomography

PVE

Partial volume effect

PVEc

Partial volume effect correction

ROI

Regions of interest

White matter

Background

Monoamine oxidase (MAO) is an enzyme of deamination of monoamine and exists in two isoforms, MAO-A and MAO-B. MAO-B is considered as a major enzyme in dopamine metabolism in the human brain, and MAO-B inhibitors are used for the treatment of Parkinson’s disease to increase the dopamine level [1]. For Alzheimer’s disease (AD), several studies reported the upregulation of MAO-B expression related to the neuroinflammatory process in the glia cells [2‐6]. So, inhibition of MAO-B is expected to have beneficial effects in AD by reducing neurodegenerative processes.

[¹¹C]-l-deprenyl-D₂ is a positron emission tomography (PET) radioligand for measurement of the MAO-B activity in the brain [7]. This radioligand was used for many PET studies to evaluate MAO-B inhibitors’ occupancy [8, 9], pathology of AD [10‐12], amyotrophic lateral sclerosis (ALS) [13], traumatic brain injury [14], and epilepsy [15‐17]. In addition to the clinical studies, [¹¹C]-l-deprenyl-D₂ showed good result reproducibility in a test-retest protocol [18].

Recently, we reported the brain occupancy of MAO-B using [¹¹C]-l-deprenyl-D₂ after administration of a MAO-B inhibitor, sembragiline, in controls and patients with AD [9]. Although the good reproducibility of [¹¹C]-l-deprenyl-D₂ has already been reported, confirmation in test-retest variability studies by using identical protocol settings, including radioligand production and PET machine, is helpful for accurate interpretation of occupancy. Additionally, age effect of [¹¹C]-l-deprenyl-D₂ should be estimated since an increase of MAO-B expression has been reported in elderly subjects by postmortem [19] and in vivo PET [20] studies. The partial volume effect (PVE) should be also considered in the PET studies for aged subjects or AD patients with brain atrophy [21, 22].

In this study, we focused on three issues. First, we evaluated the test-retest variability of [¹¹C]-l-deprenyl-D₂ in the healthy subjects who were scanned twice. Second, the correlation between MAO-B activity and age was estimated. Finally, the effect of partial volume effect correction (PVEc) for the reproducibility was also estimated.

Methods

Subjects

Six healthy volunteers (age range, 21–62 years; mean ± SD, 39.0 ± 17.0; four males, two females) were enrolled in the study. None had a history of present or past psychiatric, neurological, or somatic disorders, or alcohol or drug-related problems. They took no medication at the time of the study. After thorough explanation of the study, written informed consent was obtained from all participants. The study was approved by the Regional Ethical Review Board in Stockholm, Sweden, and the Radiation Safety Committee at the Karolinska University Hospital Solna in Stockholm, Sweden.

PET procedures

[¹¹C]-l-deprenyl-D₂ was prepared by N-methylation of the desmethyl l-deprenyl-D₂ precursor using [¹¹C]methyl triflate as previously reported [9]. PET scans were carried out with the ECAT Exact HR 47 (Siemens/CTI, Knoxville, TN, USA), with an in-plane and an axial resolution of 3.6 and 4.0 mm at full width at half maximum (FWHM), respectively. A head fixation system with an individual plaster helmet was used. A 5-min transmission scan was performed using three rotating ⁶⁸Ge rod sources. Dynamic PET scan was performed for 63 min (10 s × 9, 15 s × 2, 20 s × 3, 30 s × 4, 1 min × 4, 3 min × 4, 6 min × 7) after intravenous bolus injection of [¹¹C]-l-deprenyl-D₂. Injected radioactivity was 299–520 MBq (419 ± 68 MBq), which were adjusted by body weight. Specific radioactivity was 104–341 GBq/μmol (179 ± 80 GBq/μmol) at the time of injection. Injected mass was 0.24–0.77 μg (0.50 ± 0.18 μg). Two PET scans were performed for each subject in the morning and in the afternoon on the same day.

Arterial blood sampling

Arterial blood was collected continuously for 10 min using an automated blood sampling system at a speed of 5 mL/min. Arterial blood was also drawn manually 1, 2, 4, 6, 8, 10, 15, 20, 30, 45, and 60 min after the injection for measurement of radioactivity in whole blood and plasma. The parent fraction of the radioligand was determined using a reversed-phase high-performance liquid chromatography (HPLC) method at 4, 10, 20, 30, 45, and 60 min. Plasma input function was defined as radioactivity of plasma multiplied by the percentage of unchanged radioligand.

Data analysis

PET images were reconstructed using the standard filtered back projection with a 2-mm Hanning filter, a zoom factor of 2.17, and a 128 × 128 matrix, and were corrected for attenuation and scatter. T1-weighted magnetic resonance imaging (MRI) was performed using a 1.5-T Siemens MAGNETOM Avanto for definition of anatomical brain regions and PVEc. The MR image was segmented into grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF) segments, using the SPM5 segmentation algorithm in MATLAB (Wellcome Trust Centre for Neuroimaging, London, UK; The MathWorks, Inc., Natick, MA, USA). Regions of interest (ROI) were defined as the cerebellum, hippocampus, lateral frontal cortex, lateral occipital cortex, lateral parietal cortex, lateral temporal cortex, medial frontal cortex, putamen, and thalamus using the Anatomical Automatic Labeling (AAL) template [23]. GM masking was applied to the AAL template. All MRIs and ROIs were co-registered to summated PET images with the mutual information algorithm using SPM5. Regional radioactivity was calculated for each frame, corrected for decay, and plotted vs. time.

MAO-B binding of [¹¹C]-l-deprenyl-D₂ was quantified by two tissue compartment model (2TCM) with three rate constants (K ₁, k ₂, k ₃) using metabolite-corrected plasma radioactivity as the input function. k ₄ was set as 0 according to the assumption of irreversible binding of [¹¹C]-l-deprenyl-D₂ [7, 18]. Blood volume was fixed as 5%. The λk ₃ defined as (K ₁/k ₂) × k ₃ was also calculated. These analyses were performed using the PMOD 3.4 software package (PMOD Group, Zurich, Switzerland).

PVEc

All PET data were corrected for PVE according to the method reported by Müller-Gärtner et al. [21]. In short, this PVEc corrects for spillover between GM and WM, and between GM and CSF using the segmented MR images. By assuming that the radioligand binding in WM is perfectly homogenous, every WM-voxel were replaced by an average value derived from an isolated proportion of WM at the centrum semiovale [22].

Statistics

The test-retest variability of MAO-B binding as k ₃ and λk ₃ was expressed by the absolute difference between the first and second PET scans (PET1 and PET2) relative to the mean of the two values according to the following equation [24, 25]:

$$ \%\mathrm{difference}=\left|\mathrm{PET}1-\mathrm{PET}2\right|/\left(\left(\mathrm{PET}1+\mathrm{PET}2\right)/2\right)\times 100 $$

PET1 and PET2 are the parameters (k ₃ or λk ₃) of first and second PET scans, respectively.

Intraclass correlation coefficient (ICC) was also calculated by:

$$ \mathrm{I}\mathrm{C}\mathrm{C}=\left(\mathrm{MSBS}-\mathrm{MSWS}\right)/\left(\mathrm{MSBS}+\mathrm{MSWS}\right) $$

MSBS is the mean square of between subject, and MSWS is the mean square of within subject.

The correlation between MAO-B binding as k ₃ or λk ₃ and age was estimated using the Pearson correlation coefficient.

The effect of PVEc was estimates by the %change of before and after PVEc of all parameters, K ₁, k ₂, k ₃, and λk ₃:

$$ \%\mathrm{change}=\left(\mathrm{after}\ \mathrm{PVEc}-\mathrm{before}\ \mathrm{PVEc}\right)/\mathrm{before}\ \mathrm{PVEc}\times 100 $$

In both analysis of age effect and PVEc, average values of PET1 and PET2 were used. Finally, the test-retest variability of after PVEc was estimated as same way as before PVEc.

These statistical analyses were performed using R 3.3.2 (The R Foundation, Vienna, Austria).

Results

Test-retest variability

Mean and SD values of six subjects in PET1 and PET2, mean and range of %differences, and ICC in all regions are shown in Table 1. %difference of k ₃ was 2.6% (medial frontal cortex) to 10.3% (hippocampus), and that of λk ₃ was 5.0% (thalamus) to 9.2% (cerebellum). Mean %difference of nine regions were 5.3% and 7.0% in k ₃ and λk ₃, respectively. All regions showed variability below 10%, except the hippocampus in k ₃ (10.3%). ICC of k ₃ was 0.78 (hippocampus) to 0.98 (medial frontal cortex), and that of λk ₃ was 0.78 (hippocampus) to 0.95 (thalamus). Mean ICC of nine regions were 0.94 and 0.89 in k ₃ and λk ₃, respectively.

Table 1

Mean and SD values in PET1 and PET2, mean and range of %differences, and ICC in all regions of k ₃ and λk ₃

	k ₃							λk ₃
	PET1		PET2		%dif			PET1		PET2		%dif
Region	Mean	SD	Mean	SD	Mean	Range	ICC	Mean	SD	Mean	SD	Mean	Range	ICC
Cerebellum	0.051	0.011	0.051	0.012	5.1	0.7–11.1	0.96	0.143	0.030	0.140	0.031	9.2	5.9–15.4	0.90
Hippocampus	0.103	0.023	0.108	0.017	10.3	0.2–20.6	0.78	0.288	0.028	0.285	0.047	6.4	1.0–17.6	0.78
Lateral frontal cortex	0.067	0.014	0.067	0.013	3.8	0.4–7.2	0.97	0.185	0.023	0.184	0.033	6.0	2.4–14.2	0.91
Lateral occipital cortex	0.060	0.013	0.061	0.013	6.4	1.0–15.1	0.92	0.175	0.024	0.170	0.030	8.0	3.0–15.0	0.86
Lateral parietal cortex	0.063	0.012	0.064	0.012	3.7	1.4–7.7	0.97	0.180	0.027	0.182	0.035	7.2	2.5–12.1	0.91
Lateral temporal cortex	0.065	0.015	0.063	0.015	5.9	0.1–13.7	0.95	0.201	0.029	0.199	0.041	8.3	2.2–20.0	0.86
Medial frontal cortex	0.068	0.012	0.067	0.011	2.6	1.1–4.6	0.98	0.175	0.019	0.175	0.026	5.7	2.8–10.1	0.89
Putamen	0.087	0.019	0.085	0.016	5.4	3.2–7.6	0.96	0.323	0.051	0.331	0.072	7.4	3.0–10.5	0.91
Thalamus	0.083	0.017	0.082	0.017	4.2	0.1–9.4	0.97	0.306	0.047	0.308	0.059	5.0	1.5–8.6	0.95

Age effect

The Pearson correlation coefficient and p value between k ₃ or λk ₃ and age in all regions are shown in Table 2. The highest positive correlation was observed in the hippocampus (r = 0.75 in k ₃ and 0.76 in λk ₃; Fig. 1a, b). Regardless, both results were not statistically significant (p = 0.08 and p = 0.08, respectively).

Table 2

The Pearson correlation coefficient and p value between age and parameters in all regions of k ₃ and λk ₃

	k ₃		λk ₃
Region	r	p	r	p
Cerebellum	0.58	0.23	0.56	0.25
Hippocampus	0.75	0.08	0.76	0.08
Lateral frontal cortex	0.65	0.17	0.73	0.10
Lateral occipital cortex	0.66	0.16	0.59	0.22
Lateral parietal cortex	0.70	0.13	0.64	0.18
Lateral temporal cortex	0.69	0.13	0.72	0.10
Medial frontal cortex	0.58	0.22	0.66	0.15
Putamen	0.67	0.15	0.75	0.09
Thalamus	0.69	0.13	0.63	0.18

PVEc

After PVEc, K ₁ values increased as 36.9 to 62.7% according to the age (Fig. 2). %change of λk ₃ was 23.5 to 37.0% and also correlated with age. Compared to K ₁ and λk ₃, k ₂ and k ₃ showed only small changes after PVEc (11.6 to 15.4% and −1.3 to 5.5%, respectively).

Mean and SD values of six subjects in PET1 and PET2, mean and range of %differences, and ICC after PVEc in all regions are shown in Table 3. Mean %difference of nine regions were 5.6 and 7.2% in k ₃ and λk ₃, respectively. Mean ICC of nine regions were 0.92 and 0.90 in k ₃ and λk ₃, respectively. These values were almost the same as those before PVEc.

Table 3

Mean and SD values in PET1 and PET2, mean and range of %differences, and ICC in all regions of k ₃ and λk ₃ after PVEc

	k ₃							λk ₃
	PET1		PET2		%dif			PET1		PET2		%dif
Region	Mean	SD	Mean	SD	Mean	Range	ICC	Mean	SD	Mean	SD	Mean	Range	ICC
Cerebellum	0.050	0.011	0.051	0.012	5.6	1.1–11.2	0.95	0.174	0.039	0.170	0.040	9.8	5.6–16.1	0.91
Hippocampus	0.116	0.024	0.122	0.019	10.6	0.3–23.2	0.70	0.345	0.028	0.340	0.055	7.4	1.4–17.7	0.73
Lateral frontal cortex	0.065	0.012	0.065	0.012	4.0	1.5–7.1	0.97	0.272	0.050	0.271	0.063	6.2	2.0–15.0	0.95
Lateral occipital cortex	0.059	0.010	0.059	0.012	7.2	1.4–16.7	0.86	0.243	0.039	0.233	0.047	9.1	1.3–19.8	0.84
Lateral parietal cortex	0.062	0.011	0.064	0.011	4.0	1.3–7.2	0.96	0.265	0.049	0.267	0.059	7.7	2.9–12.3	0.93
Lateral temporal cortex	0.065	0.014	0.063	0.014	6.0	0.4–14.4	0.95	0.264	0.046	0.260	0.061	9.0	2.1–22.8	0.88
Medial frontal cortex	0.065	0.010	0.065	0.010	2.2	0.5–4.2	0.98	0.265	0.041	0.267	0.052	5.1	0.0–9.1	0.94
Putamen	0.089	0.018	0.086	0.017	4.8	1.1–7.6	0.96	0.329	0.053	0.337	0.076	7.0	0.4–12.0	0.91
Thalamus	0.095	0.020	0.096	0.018	6.3	1.7–10.5	0.92	0.326	0.061	0.325	0.072	3.9	0.0–8.5	0.96

Discussion

In this study, the test-retest variability of [¹¹C]-l-deprenyl-D₂ was estimated using healthy subjects. Mean of absolute %difference in nine regions of λk ₃ was 7.0%, indicating good reproducibility. The test-retest variability of λk ₃ using %difference (not absolute difference) by Logan et al. was previously reported as −2.84 ± 7.07% [18]. The same calculation of our data yielded −1.1 ± 8.3%, indicating similar variability. ICC values were high in all regions, except in the hippocampus which was relatively low (0.78). It also indicated good reproducibility of [¹¹C]-l-deprenyl-D₂. Our research group recently reported the brain occupancy of MAO-B using [¹¹C]-l-deprenyl-D₂ after administration of a MAO-B inhibitor—sembragiline [9]. The study reported that oral administrations of 1–5 mg sembragiline induced near-maximal inhibition of brain MAO-B, and MAO-B occupancy was correlated with the plasma concentration of sembragiline in patients with AD. The good test-retest reproducibility of the present study using same procedure of [¹¹C]-l-deprenyl-D₂ preparation and same PET camera corroborates the findings of our previous study.

Although λk ₃ is generally considered to be a more stable outcome measure than k ₃ [7, 18], k ₃ showed similar %difference as λk ₃ (5.3 vs 7.0%) in the present study. k ₃ values also showed better ICC than those of λk ₃ (mean value, 0.94 vs 0.89). These findings indicate that k ₃ may be independently used for further studies such as comparison between patients and healthy controls or target occupancy of MAO-B inhibitors. Obvious regional differences of reproducibility were only observed in the hippocampus. The reason of low reproducibility in the hippocampus is not clear, but one possibility is that its high k ₃ value (the highest among all regions) may have induced a large variability.

In this study, two PET measurements were performed in 1 day, in the morning and afternoon. Several studies suggested that dopamine system was affected by the circadian rhythm [26‐28]. Especially, one rodent study reported that MAO-A expression was regulated by the clock-component gene [29]. However, our result did not show the relation between the MAO-B binding and the time of PET measurements.

A moderate age effect on λk ₃ values was observed in all regions. The degree of increase (6.3% per decade) was similar as the previously reported value by Fowler et al., at 7.1% per decade [20]. One postmortem study also reported increasing of MAO-B protein in the human brain according to age [19]. Our PET study confirmed both findings of postmortem and in vivo human brain studies. Among all regions, the hippocampus showed the highest correlation with age effect although it did not reach statistical significance and the reproducibility was relatively low as discussed above. Since the hippocampus is thought to be especially impacted in AD [30, 31], the present findings suggest the increase of MAO-B activity may have an important role about the pathology of AD.

PVE should be considered in PET studies when brain atrophy is observed in aged subjects or patients with disorders such as AD. Additionally, PVE is larger using a low resolution PET camera than a high resolution one. This study included elderly subjects and was conducted using relatively low resolution PET camera system compared to recent PET systems like the high resolution research tomograph (HRRT) with 1.5 mm FWHM [32]. In the present study, %change of K ₁ after PVEc was correlated with age. It indicates that the brain of aged subjects was more affected by the PVE compared to younger subject due to the brain atrophy. Meanwhile, k ₂ and k ₃ did not show any clear change after PVEc. λk ₃ was also moderately affected by PVEc and correlated with age since it is partially determined by K ₁/k ₂. Nevertheless, although the value itself of λk ₃ was increased in aged subjects, test-retest variability of λk ₃ did not change after PVEc. This indicates that PVEc can reliably keep reproducibility even in the case of elderly subjects with brain atrophy.

There are several imitations in this study. Although only six subjects were included and it is relatively small sample size, the number were similar as previous test-retest studies about [¹¹C]-l-deprenyl-D₂ by Logan et al. (n = 5) [18] and other PET radioligands (n = 6–8) [25, 33]. However, the studies about age effect included larger number generally [20, 34, 35]. So, the present result about the age effect might be preliminary. Additionally, only healthy control subjects were included in this study. It is difficult to extrapolate our findings about PVEc to AD patients because the elderly ones showed slight atrophy but not pathological. To more accurately estimate the effects of PVEc, further studies with AD patients and aged control subjects who showed strong atrophy will be needed.

Conclusions

The present results indicate that k ₃ and λk ₃ of [¹¹C]-l-deprenyl-D₂ are reliable parameters for test-retest reproducibility with healthy subjects both before and after PVEc. As the number of subjects was relatively small and only healthy subjects were included, the studies with patients of larger sample size are required for further clinical applications.

Acknowledgements

We thank all members of the Karolinska Insitutet PET Centre for assistance with the PET experiments. RSM was recipient of a post doc fellowship (CNPq-23364/2014-7).

Funding

This work was partially supported by GE Healthcare Ltd., UK.

Authors’ contributions

PS, AT, and CH designed the study and wrote the protocol. PS and SN conducted the PET experiment. RA, PS, AT, and RSM analyzed the data. RA wrote the first draft of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Not applicable

The study was approved by the Regional Ethical Review Board in Stockholm, Sweden, and the Radiation Safety Committee at the Karolinska University Hospital in Solna in Stockholm, Sweden. After thorough explanation of the study, written informed consent was obtained from all participants.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Finberg JPM. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther. 2014;143:133–52.CrossRefPubMed

Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int. 2011;58:60–8.CrossRefPubMed

Emilsson L, Saetre P, Balciuniene J, Castensson A, Cairns N, Jazin EE. Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer’s disease patients. Neurosci Lett. 2002;326:56–60.CrossRefPubMed

Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 1994;62:15–30.CrossRefPubMed

Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer’s disease: a biochemical and autoradiographical study. Neuroscience. 1991;45:1–12.CrossRefPubMed

Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol. 1990;80:419–25.CrossRefPubMed

Fowler JS, Wang GJ, Logan J, Xie S, Volkow ND, MacGregor RR, et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med. 1995;36:1255–62.PubMed

Hirvonen J, Kailajärvi M, Haltia T, Koskimies S, Någren K, Virsu P, et al. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 2009;85:506–12.CrossRefPubMed

Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, et al. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline. Eur J Nucl Med Mol Imaging. 2017;44(3):382–91.

10.

Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53:37–46.CrossRefPubMed

11.

Choo ILH, Carter SF, Schöll ML, Nordberg A. Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients. Eur J Nucl Med Mol Imaging. 2014;41:2120–6.CrossRefPubMed

12.

Santillo AF, Gambini JP, Lannfelt L, Långström B, Ulla-Marja L, Kilander L, et al. In vivo imaging of astrocytosis in Alzheimer’s disease: an 11C-L-deuteriodeprenyl and PIB PET study. Eur J Nucl Med Mol Imaging. 2011;38:2202–8.CrossRefPubMed

13.

Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius S-M, et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci. 2007;255:17–22.CrossRefPubMed

14.

Fowler JS, Volkow ND, Cilento R, Wang GJ, Felder C, Logan J. Comparison of brain glucose metabolism and monoamine oxidase B (MAO B) in traumatic brain injury. Clin Positron Imaging. 1999;2:71–9.CrossRefPubMed

15.

Bergström M, Kumlien E, Lilja A, Tyrefors N, Westerberg G, Långström B. Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl—analysis of kinetic data. Acta Neurol Scand. 1998;98:224–31.CrossRefPubMed

16.

Kumlien E, Bergström M, Lilja A, Andersson J, Szekeres V, Westerberg CE, et al. Positron emission tomography with [11C]deuterium-deprenyl in temporal lobe epilepsy. Epilepsia. 1995;36:712–21.CrossRefPubMed

17.

Kumlien E, Nilsson A, Hagberg G, Långström B, Bergström M. PET with 11C-deuterium-deprenyl and 18F-FDG in focal epilepsy. Acta Neurol Scand. 2001;103:360–6.CrossRefPubMed

18.

Logan J, Fowler JS, Volkow ND, Wang GJ, MacGregor RR, Shea C. Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain. Nucl Med Biol. 2000;27:43–9.CrossRefPubMed

19.

Tong J, Meyer JH, Furukawa Y, Boileau I, Chang L-J, Wilson AA, et al. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab. 2013;33:863–71.CrossRefPubMedPubMedCentral

20.

Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18:431–5.CrossRefPubMed

21.

Müller-Gärtner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992;12:571–83.CrossRefPubMed

22.

Schain M, Tóth M, Cselényi Z, Stenkrona P, Halldin C, Farde L, et al. Quantification of serotonin transporter availability with [11C]MADAM—a comparison between the ECAT HRRT and HR systems. Neuroimage. 2012;60:800–7.CrossRefPubMed

23.

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.CrossRefPubMed

24.

Collste K, Forsberg A, Varrone A, Amini N, Aeinehband S, Yakushev I, et al. Test–retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects. Eur J Nucl Med Mol Imaging. 2016;43:173–83.CrossRefPubMed

25.

Nord M, Finnema SJ, Schain M, Halldin C, Farde L. Test–retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. Eur J Nucl Med Mol Imaging. 2014;41:301–7.CrossRefPubMed

26.

Cervenka S, Halldin C, Farde L. Age-related diurnal effect on D2 receptor binding: a preliminary PET study. Int J Neuropsychopharmacol. 2008;11:671–8.CrossRefPubMed

27.

Minton GO, Young AH, McQuade R, Fairchild G, Ingram CD, Gartside SE. Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder. Neuropsychopharmacology. 2009;34:2265–74.CrossRefPubMed

28.

Huang J, Zhong Z, Wang M, Chen X, Tan Y, Zhang S, et al. Circadian modulation of dopamine levels and dopaminergic neuron development contributes to attention deficiency and hyperactive behavior. J Neurosci. 2015;35:2572–87.CrossRefPubMedPubMedCentral

29.

Hampp G, Ripperger JA, Houben T, Schmutz I, Blex C, Perreau-Lenz S, et al. Regulation of monoamine oxidase A by circadian-clock components implies clock influence on mood. Curr Biol. 2008;18:678–83.CrossRefPubMed

30.

Braskie MN, Thompson PM. A focus on structural brain imaging in the Alzheimer’s disease neuroimaging initiative. Biol Psychiatry. 2014;75:527–33.CrossRefPubMed

31.

de Flores R, La Joie R, Chételat G. Structural imaging of hippocampal subfields in healthy aging and Alzheimer’s disease. Neuroscience. 2015;309:29–50.CrossRefPubMed

32.

Varrone A, Sjöholm N, Eriksson L, Gulyás B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639–50.CrossRefPubMed

33.

Jučaite A, Cselényi Z, Arvidsson A, Ahlberg G, Julin P, Varnäs K, et al. Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain—a PET study in control subjects. EJNMMI Res. 2012;2:15.CrossRefPubMedPubMedCentral

34.

Fazio P, Schain M, Mrzljak L, Amini N, Nag S, Al-Tawil N, et al. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D 2/3 receptors and sub-cortical volumes in the human basal ganglia: a PET study with 18 F-MNI-659 and 11 C-raclopride with correction for partial volume effect. Neuroimage. 2017;152:330–9.CrossRefPubMed

35.

Matuskey D, Worhunksy P, Correa E, Pittman B, Gallezot J-D, Nabulsi N, et al. Age-related changes in binding of the D2/3 receptor radioligand [11C](+)PHNO in healthy volunteers. Neuroimage. 2016;130:241–7.CrossRefPubMedPubMedCentral

Titel: Test-retest reproducibility of [11C]-l-deprenyl-D2 binding to MAO-B in the human brain
verfasst von: Ryosuke Arakawa
Per Stenkrona
Akihiro Takano
Sangram Nag
Rafael S. Maior
Christer Halldin
Publikationsdatum: 01.12.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: EJNMMI Research / Ausgabe 1/2017
Elektronische ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-017-0301-4

Springer Medizin

Abstract

Background

Results

Conclusions

Background

Methods

Subjects

PET procedures

Arterial blood sampling

Data analysis

PVEc

Statistics

Results

Test-retest variability

Age effect

PVEc

Discussion

Conclusions

Acknowledgements

Funding

Authors’ contributions

Competing interests

Consent for publication

Ethics approval and consent to participate

Publisher’s Note

Weitere Artikel der Ausgabe 1/2017

Diagnostic accuracy of coronary opacification derived from coronary computed tomography angiography to detect ischemia: first validation versus single-photon emission computed tomography

Initial evaluation of the Celesteion large-bore PET/CT scanner in accordance with the NEMA NU2-2012 standard and the Japanese guideline for oncology FDG PET/CT data acquisition protocol version 2.0

18F-FDG-labeled red blood cell PET for blood-pool imaging: preclinical evaluation in rats

Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?

Comparison of machine learning methods for classifying mediastinal lymph node metastasis of non-small cell lung cancer from 18F-FDG PET/CT images

FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study